Seer (NASDAQ:SEER) Posts Quarterly Earnings Results, Hits Estimates

by · The Cerbat Gem

Seer (NASDAQ:SEER – Get Free Report) posted its earnings results on Wednesday. The company reported ($0.30) earnings per share for the quarter, meeting the consensus estimate of ($0.30), FiscalAI reports. The firm had revenue of $2.79 million during the quarter, compared to analyst estimates of $3.60 million. Seer had a negative net margin of 443.96% and a negative return on equity of 26.04%.

Here are the key takeaways from Seer’s conference call:

  • Seer reaffirmed its full-year 2026 revenue guidance of $16 million to $18 million, saying it still expects momentum to build through the year despite a soft first quarter and continued NIH funding pressure.
  • Q1 revenue fell to $2.8 million from $4.2 million a year ago, reflecting weak academic/government funding, heavier competitive pressure, and some disruption from a commercial leadership transition.
  • The company said its scientific validation continues to accelerate, with 84 peer-reviewed publications, preprints, and reviews now supporting the Proteograph platform, up sharply from 42 a year ago.
  • Seer highlighted major progress in population-scale studies, including the PRECISE-SG100K biobank program and other large cohorts, which management believes could help drive broader adoption and larger future revenue opportunities.
  • The company emphasized strong cost discipline, as operating expenses fell to $18.2 million from $22.8 million a year earlier, while it ended Q1 with $219.5 million in cash and investments and said it has enough liquidity to reach cash-flow breakeven.

Seer Trading Down 2.7%

NASDAQ:SEER traded down $0.05 during trading hours on Wednesday, reaching $1.77. 349,168 shares of the company were exchanged, compared to its average volume of 332,477. The stock’s 50-day moving average is $1.81 and its 200-day moving average is $1.90. The firm has a market cap of $99.86 million, a PE ratio of -1.38 and a beta of 1.63. Seer has a twelve month low of $1.65 and a twelve month high of $2.41.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. TD Cowen upgraded shares of Seer to a “strong-buy” rating in a research report on Monday, April 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Seer in a research report on Tuesday, April 21st. Finally, Canaccord Genuity Group assumed coverage on shares of Seer in a research report on Monday, May 4th. They set a “buy” rating and a $4.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Seer has an average rating of “Buy” and a consensus price target of $4.00.

Check Out Our Latest Analysis on Seer

Hedge Funds Weigh In On Seer

Large investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. grew its holdings in shares of Seer by 51.6% during the first quarter. Goldman Sachs Group Inc. now owns 170,897 shares of the company’s stock worth $289,000 after buying an additional 58,173 shares in the last quarter. Jane Street Group LLC grew its holdings in shares of Seer by 33.3% during the first quarter. Jane Street Group LLC now owns 254,174 shares of the company’s stock worth $430,000 after buying an additional 63,432 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Seer by 16.5% during the second quarter. Geode Capital Management LLC now owns 509,727 shares of the company’s stock worth $1,091,000 after buying an additional 72,265 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Seer during the second quarter worth $172,000. Finally, Occudo Quantitative Strategies LP purchased a new stake in shares of Seer during the second quarter worth $25,000. 75.20% of the stock is currently owned by institutional investors and hedge funds.

About Seer

(Get Free Report)

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.

Further Reading